Tag: hypertrophic cardiomyopathy (HCM)

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023/Genomic Medicine

Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

23-HVI-4172009 CQD 650×450-2
August 29, 2023/Research

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

January 27, 2023/Clinical Cardiology

Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning

An abundance of promising studies are on the horizon


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-HVI-3393756_echo-showing-obstructive-HCM_ 650×450
December 2, 2022/Imaging

VALOR-HCM Substudy: Mavacamten Improves Left Ventricular Diastolic Function

Gains are associated with clinical and biomarker benefits in obstructive HCM

January 6, 2022/Research

Study Confirms Quality-of-Life Benefits of Myectomy in Obstructive HCM

Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up

November 18, 2021/Clinical Cardiology

In Obstructive Hypertrophic Cardiomyopathy, One Size Does Not Fit All

Why we favor a tailored approach to relieve LVOT obstruction

September 2, 2021/Cardiology

Pediatric Waitlist and Heart Transplant Mortality Rates Similar in All Cardiomyopathy Phenotypes

VADs remain underutilized in non-dilated cardiomyopathy patients

cardiac magnetic resonance images showing hypertrophic cardiomyopathy
March 9, 2020/Research

Hypertrophic Cardiomyopathy: Signs of Progress Toward a Medical Therapy and Refined Risk Prediction

New and ongoing studies aim to reduce the need for surgery, improve risk stratification

BackPage 1 of 2Next